{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":6,"podcast":6,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06111235\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06111235","nct_id":"NCT06111235","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06111235. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Following screening confirmation of IR-NMIBC and complete resection of the tumor, participants will be treated with adjuvant cretostimogene.","label":"Cretostimogene after TURBT","type":"EXPERIMENTAL"},{"description":"Following screening confirmation of IR-NMIBC and complete resection of tumor, participants will enter surveillance.\n\nParticipants who recur with IR-NMIBC after TURBT and surveillance will be offered treatment with cretostimogene as per the treatment schedule in Arm A. This arm will be called the Extension Arm.","label":"Observation after TURBT","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2029-02","type":"ESTIMATED"},"conditions":["Non Muscle Invasive Bladder Cancer","Urologic Cancer","Bladder Cancer","Urothelial Carcinoma"],"enrollment":{"count":367,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cretostimogene Grenadenorepvec","type":"DRUG"},{"name":"n-dodecyl-B-D-maltoside","type":"OTHER"}],"last_update":"2026-07-01","lead_sponsor":"CG Oncology, Inc.","official_title":"A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence Free Survival (RFS)","timeFrame":"29 months"}],"references":[{"citation":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16.","pmid":"27317986","type":"BACKGROUND"}],"start_date":{"date":"2023-12-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","url":"https://clinicaltrials.gov/study/NCT06111235"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06111235"}